The role of BRAF testing of Rathke’s cleft cysts to identify missed papillary craniopharyngioma
This study highlights the potential value of BRAF testing in RCCs to identify missed pCP, which is an especially timely finding given the advent of primary medical therapy with BRAF inhibition for pCP. In the absence of guidelines advising on the use of BRAF studies in sellar lesions, we suggest consideration of BRAF testing of all RCCs, particularly if there is squamous metaplasia or disease recurrence.
Authors
- Barbara Koszyca
- Alex D. H. Brown (ORCID: https://orcid.org/0000-0003-2112-3918)
- Esther Quick
- Sunita M C De Sousa (ORCID: https://orcid.org/0000-0003-0127-6482)
- Nicholas G. Candy (ORCID: https://orcid.org/0000-0002-8826-1840)
- Stephen Santoreneos
- Nick Vrodos
- Edward Mignone (ORCID: https://orcid.org/0009-0007-8605-0525)
- David J. Torpy (ORCID: https://orcid.org/0000-0002-5069-0981)
- Ian Chapman
Institutions
- South Australia Pathology (AU)
- Royal Adelaide Hospital (AU)
- University of South Australia (AU)
- Flinders Medical Centre (AU)
- Basil Hetzel Institute (AU)
- Centre for Cancer Biology (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Pituitary
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1007/s11102-025-01501-8
- Citations
- 5
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.47
Funders
- University of Adelaide